Showing results (111-120 of 235) with videos related to
Sort By:
Pageof 24
Lipids in Health and Disease|August 20, 2016
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment centerParth Shah, Charles J Glueck, Vybhav Jetty, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 23, 2024
Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective studyParth Shah, Megan White, Alex Sievert, et al.Cancers|November 13, 2025
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted TherapiesPetar Brlek, Vedrana Škaro, Nenad Hrvatin, et al.Journal of Clinical Periodontology|April 1, 2025
A Real-World Evidence Study Evaluating Oral-Health-Related Quality of Life Following the Use of Anti-Sensitivity Toothpaste for Self-Reported Dentine Hypersensitivity ManagementRoberta Grimaldi, Sarah R Baker, Parth Shah, et al.Croatian Medical Journal|June 13, 2024
Genomic sequencing for newborn screening: current perspectives and challengesNidhi Shah, Petar Brlek, Luka Bulić, et al.Journal of Clinical Ultrasound : JCU|February 16, 2016
Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitorsSherif Moustafa, Thai H Ho, Parth Shah, et al.Preventive Medicine|August 3, 2021
Time and geographic variations in human papillomavirus vaccine uptake in Washington stateNastaran Pourebrahim, Parth Shah, Trang VoPham, et al.Lipids in Health and Disease|March 13, 2016
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapyCharles J Glueck, Parth Shah, Naila Goldenberg, et al.Lipids in Health and Disease|January 25, 2017
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization studyParth Shah, Charles J Glueck, Naila Goldenberg, et al.Hepatology (Baltimore, Md.)|March 26, 2019
Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a PatientsVinay Sundaram, Parth Shah, Robert J Wong, et al.Pageof 24